2 ASX 200 shares tipped to rise 39% to 130%

If you are on the hunt for some big returns for your portfolio, then it could be worth looking at the two ASX 200 shares in this article.

That's because analysts are tipping them to rise between 39% and 130% over the next 12 months.

Here's what they are recommending:

Megaport Ltd (ASX: MP1)

The team at Morgans is positive on this cloud infrastructure company and believes it could be an ASX 200 share to snap up.

In response to recent updates, the broker has lifted its earnings estimates and valuation accordingly.

This has seen Morgans retain its buy rating with a new price target of $27.00. Based on its current share price of $19.38, this implies potential upside of 39% for investors.

Commenting on the company, Morgans said:

MP1 recently raised its FY27 EBITDA guidance by 25%. The compute and network businesses continue to deliver above expectations and MP1 announced three new AI infrastructure contracts with a Total Contract Value of ~A$1bn. Collectively these set a glide path for annualised EBITDA in excess of $850m. We upgrade our EPS forecasts materially. Our Target Price lifts to A$27 per share and we retain our BUY recommendation.

Mesoblast Ltd (ASX: MSB)

Another ASX 200 share that could rise materially according to analysts is biotechnology stock Mesoblast. 

Bell Potter is positive on the company and sees significant value in its shares at current levels.

This morning, it has retained its buy rating and $4.45 price target on Mesoblast shares. Based on its current share price of $1.94, this implies potential upside of approximately 130%.

The broker highlights that there are a number of important events on the horizon. 

The short term outlook for Mesoblast's revenue growth remains highly attractive. Pivotal events for valuation are approaching, including the interim readout on the adult GvHD study (1QCY27) and the headline data from the chronic lower back pain trial (CLBP) due mid CY27. Both are substantially larger markets than paediatric GvHD, nevertheless the market remains cautious.

Bell Potter then adds:

MSB remains an enigma for most Australian long only institutions, despite having achieved multiple clinical trial successes, product approvals and revenues likely to exceed US$200m in FY27. We expect this information gap will close over the coming year as the company delivers on additional wins in the clinic. To this end, Dr Doug Beall is a leading investigator and KOL in the CLBP trial for Rexlemestrocel and is expected to present at the upcoming AGM. We maintain our buy rating and PT $4.45.

The post 2 ASX 200 shares tipped to rise 39% to 130% appeared first on The Motley Fool Australia.

Motley Fool contributor James Mickleboro has positions in Megaport. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Megaport. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026